SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
NGM Biopharmaceuticals, Inc. (NGM) .
本页证实的标准:
- VALUE (100/100, 通过) — 分析师目标价暗示上行空间 (+971.4%).
- 分析师共识目标价 $16.50 (+971.4% 上行空间) — 华尔街分析师认为存在显著上行潜力。
SharesGrow 综合评分： 49/100 其中 3/7 项标准通过。
SharesGrow 7-Criteria Score
✓
价值
100/100
Price-to-Earnings & upside
Proven by this page
✓
健康
100/100
Debt-to-Equity & liquidity
→ Health
估值概览 — NGM
估值倍数
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率28.76
EV/EBITDA0.0
每股数据
EPS (TTM)$-1.73
每股账面价值$0.00
每股营收$0.05
每股自由现金流$0.00
收益率与内在价值
盈利收益率N/A
股息收益率0.00%
分析师目标价$16.50 (+971.4%)
P/E Ratio & Earnings Yield
每股收益 (EPS) 历史
| Year |
EPS（稀释） |
营收 |
净利润 |
净利润率 |
| 2016 |
$-0.13 |
$85.59M |
$-6.92M |
-8.1% |
| 2017 |
$-0.26 |
$77.14M |
$-14.16M |
-18.4% |
| 2018 |
$-0.01 |
$108.67M |
$-493K |
-0.5% |
| 2019 |
$-0.57 |
$103.54M |
$-28.5M |
-27.5% |
| 2020 |
$-1.37 |
$87.37M |
$-93.99M |
-107.6% |
| 2021 |
$-1.48 |
$77.88M |
$-113.83M |
-146.2% |
| 2022 |
$-1.99 |
$55.33M |
$-159.09M |
-287.5% |
| 2023 |
$-1.73 |
$4.42M |
$-142.38M |
-3223.3% |
